Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology is currently positioned for success due to its strong clinical data and upcoming catalysts, including the topline data from the registration-directed Ph.3 BOND-003 trial and the completion of the BLA filing for cretostimogene. Its unique mechanism and potential to address multiple NMIBC settings sets it apart from competitors and makes it a potential go-to treatment option. While there are some developmental risks, CG Oncology's strong potential for market-leading share and favorable safety profile justify an Outperform, Speculative Risk rating.

Bears say

CG Oncology is making slow progress with its trials and BLA filing for cretostimogene grenadenorepvec and there is a lack of decisive data to confidently support its potential value in the market. Additionally, there are potential risks such as disappointing data updates and concentration risk as a single-asset company. There is a possibility for upside following near-term catalysts, but further evidence is needed to justify a positive outlook.

CGON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 10 analysts, CGON has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.